Belimumab Injection
BENLYSTA (belimumab) injection,
for subcutaneous use Initial U.S. Approval: 2011
BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of:
• patients aged 5 years and older with active systemic lupus erythematosus (SLE) who are receiving standard therapy;
• patients aged 5 years and older.
Active ingredient: belimumab. Inactive ingredients (intravenous): citric acid, polysorbate 80, sodium citrate, sucrose. Inactive Ingredients (subcutaneous): L-arginine hydrochloride, L-histidine, L-histidine monohydrochloride, polysorbate 80, sodium chloride.
Facts about Belimumab Injection
Approval Date: 2011
Proprietary Name: On Request
Active Ingredient(s): Belimumab Injection
Dosage Forms And Strengths: • Intravenous Infusion: − For Injection: 120 mg or 400 mg of belimumab lyophilized powder in single-dose vial for reconstitution and dilution prior to intravenous infusion. • Subcutaneous Injection: −Injection: 200 mg/mL of belimumab in single-dose prefilled autoinjector or single-dose prefilled syringe.
International non-proprietary name (INN) or common name: Belimumab Injection
Therapeutic area (MeSH): active systemic lupus erythematosus (SLE or lupus) or active lupus nephritis (lupus-related kidney inflammation)
Marketing: GlaxoSmithKline
EMA Approved: 2011
Summary of FDA approved use on approval date: Click Here
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import Belimumab Injection” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Contact Info
CORPORATE OFFICE:
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
EMAIL ID:
info@indianpharmanetwork.co.in
FAX NUMBER:
+91-11-26532129
Query For Belimumab Injection
Approved accessible "Belimumab Injection"
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States[8] and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis.Belimumab is indicated for the treatment of active systemic lupus erythematosus and active lupus nephritis.
• BENLYSTA is a prescription medicine used to treat people with active systemic lupus erythematosus (SLE or lupus) or active lupus nephritis (lupus-related kidney inflammation), who are receiving other lupus medicines.
• BENLYSTA contains belimumab which is in a group of medicines called monoclonal antibodies. Lupus is a disease of the immune system (the body system that fights infection). When given together with other medicines for lupus, BENLYSTA decreases lupus disease activity more than other lupus medicines alone.
How can 1 go about obtaining Belimumab Injection?
If Belimumab Injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
BENLYSTA (belimumab) injection, for subcutaneous use Initial U.S. Approval: 2011
References
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398
Free Customer Support
info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in